Trial · NCT05422885
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Neurovascular Coupling | Screening, 8, and 14 weeks | Change in cerebral blood flow during an N-back cognitive task using transcranial doppler ultrasound. |
| Primary | Executive Function | Baseline, 8, and 14 weeks | Assess change in executive cognitive function using TRAILS test, corrected for response time. Higher scores indicate worse executive functioning. |
| Primary | Gait Speed | Baseline, 8, and 14 weeks | Assess change in gait speed. Performed without a distracting cognitive task. |
| Primary | Montreal Cognitive Assessment (MoCA) Score | Baseline, 8, and 14 weeks | The Montreal Cognitive Assessment evaluates global cognition. Scores range from 0-30 points, with higher scores indicating better cognition |
| Secondary | Physical Performance | Baseline, 8, and 14 weeks | Assessment of overall physical function using the short physical performance battery (SPPB) scored from 0-12, based on a composite of balance, strength, and walking speed. Higher scores indicate better mobility. |
| Secondary | Mobility | Baseline, 8, and 14 weeks | Test of mobility using timed up and go test, including standing from a chair, walking, and turning. |
| Secondary | Grip Strength | Baseline, 8, and 14 weeks | Measure of grip strength using a hand dynamometer. |
| Secondary | Gait Speed During Cognitive Task | Baseline, 8, and 14 weeks | Measure of gait speed during a cognitive task. |
| Secondary | P16 ink4a Expression in CD3 Positive Cells | Screening and 14 weeks | Measure of P16 ink4a expression in senescent CD3 lymphocytes in the blood. |
| Secondary | SASP Factors in Blood and Urine | Screening and 14 weeks | Measure of the senescence-associated biomarkers IL-1alpha picogram/mL and IL-6 picogram/mL. |
| Secondary | SASP Factors in Blood and Urine | Screening and 14 weeks | Measure of the senescence-associated biomarkers MMP-9 nanograms/mL and MMP-12 nanograms/mL. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05422885/registered